Hematopoietic stem cell transplantation (commonly known as bone marrow transplantation) is the only radical treatment for hematologic malignant diseases, including leukemia, lymphoma, and myeloma, among which allogeneic hematopoietic stem cell transplantation (allogeneic transplantation) is the preferred treatment for the more malignant diseases such as acute lymphoblastic leukemia, highly aggressive lymphoma, and myeloma. (bone marrow source) and age restriction (generally below 45 years old), which leads to its inability to meet the treatment requirements of clinical patients; while autologous hematopoietic stem cell transplantation (autologous transplantation) is more widely performed clinically than allogeneic transplantation because it is relatively unaffected by the above factors, but it has a relatively higher chance of disease recurrence compared to allogeneic transplantation. Therefore, how to reduce the risk of disease recurrence after autologous transplantation is a hot topic of current research. Modern studies have shown that the recurrence of hematologic malignancies after autologous transplantation is mostly at the primary site or associated with the primary disease, which suggests that factors such as the disease not eradicated before transplantation or the residual tumor cells in the transplanted stem cells may be the main causes of recurrence. At present, the comprehensive program of autologous NK cell transplantation combined with Chinese medicine in our department has been applied in clinical practice and has achieved satisfactory results. Briefly, we introduce the following: First, in terms of hematopoietic stem cell purification, we apply the blood cell separator for hematopoietic stem cell collection of peripheral blood CD34+ cells to purify the stem cells as much as possible and reduce the possibility of tumor residue in the returned grafts; Second, we infuse the NK cells expanded by in vitro culture after autologous transplantation chemotherapy, and the infused NK cells play a further role in removing some of the tumor cells resistant to chemotherapy drugs in vivo. Thirdly, after the transplantation, we carry out systematic Chinese medicine treatment and take internal Chinese medicine according to the different disease states of the patients in order to quickly restore the normal immune function of the patients and prevent the recurrence of the disease. Since the transplantation of hematopoietic stem cells in our department last year, autologous hematopoietic stem cell transplantation with NK cells combined with Chinese medicine has treated many patients with different diseases with satisfactory clinical efficacy, which is worthy of further development and promotion.